知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.028 seconds)

    DAGRS: Directed Antigonists to Cancer Cell Growth Signals
    3.
    发明申请
    DAGRS: Directed Antigonists to Cancer Cell Growth Signals 审中-公开

    公开(公告)号：US20180016305A1

    公开(公告)日：2018-01-18

    申请号：US15649515

    申请日：2017-07-13

    Applicant: David I. Cohen

    Inventor： David I. Cohen

    IPC: C07K14/005 ,  G06F19/22 ,  G06F19/24 ,  G06F19/18 ,  C12N9/12 ,  A61K38/00

    CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K2319/09 ,  C12N9/12 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/15051 ,  C12N2740/16022 ,  C12N2740/16033 ,  C12N2740/16051 ,  C12Y207/11001 ,  G16B20/00 ,  G16B30/00 ,  G16B40/00

    Abstract: The present invention describes a unique method of treating cancer with the administration of an improved DAGRS™ construct which functions as a humanized agent specifically targeting cancer cells in vivo. A specific DAGRS™ is described constructed of a humanized drug delivery biologic, carboxyl to an Apoptin fragment consisting of Apoptin's proline-rich SH3-binding fragment, a spacer, and a MAP kinase (MAPK) phosphorylation site, in replacement of the SH3-binding domain at HIV-1 TAT's amino terminus. Apoptin is a viral protein with incumbent immunogenicity and toxicity in humans. Improved DAGRS™ constructs are described that replace the viral VP3 peptide with human AKT peptide or derivative, all equivalently spaced 11 amino acids from the initial proline to the beginning of the MAPK phosphorylation site, through which technology the DAGRS™ is fully humanized. DAGRS™ provide for improved bioavailability, enhanced specific activity, and low toxicity for in vivo treatment of cancer. DAGRS™ are a superior method for targeting any oncogene with an inhibitory peptide.An algorithm for “humanization” is described through which human functional equivalent(s) to viral product(s) are identified by alignment of peptides anchored at each end by matching functional motifs that are spaced equivalently distant in the two aligned peptides. The algorithm totally disregards the primary amino acid composition of the spacer, and as such separates from current computer algorithms that prioritize primary amino acid alignments. Accounting for spacing dictates that functional domains be oriented correctly in three dimensions. The invention taught here can be developed into computer algorithms for rapidly identifying these anchored alignments, and thereafter developing safe humanized drugs from disruptive viral activities. Computers once taught the basic rules for anchoring equivalents, can improve on the basic algorithm through artificial intelligence to expand drug development.

Patent Agency Ranking